Q-omics provides the consensus-scored CBX1 profile across patient tissues and cancer cell-line models. CBX1 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, CBX1 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, CBX1 protein abundance shows 27,856 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight MESO, HNSC, and LSCC as cancer lineages where CBX1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CBX1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CBX1 survival associations across molecular data types. CBX1 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (4) and mass-spec protein abundance (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CBX1 RNA expression–survival associations across cancer types. High CBX1 expression shows unfavorable associations in MESO, ACC, LIHC and KIRP, but favorable associations in UCS and KIRC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for CBX1 RNA expression.
This table summarizes CBX1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 12. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CBX1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CBX1 shows lower tumor expression in THCA and KICH and higher tumor expression in HNSC, LUSC, LIHC and LUAD. The HNSC box plot shows higher CBX1 RNA expression in tumor versus normal tissue (log2 FC = +1.500, t-test p < 0.001).
This table shows molecular features associated with CBX1 in patient tissues and cancer cell lines. In patient samples, CBX1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, CBX1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
